Ito Arisa, Matsumoto Hidetaka, Morimoto Masahiro, Mimura Kensuke, Akiyama Hideo
Department of Ophthalmology, Gunma University School of Medicine, Gunma, Japan.
Ophthalmologica. 2017;238(4):236-242. doi: 10.1159/000479937. Epub 2017 Sep 13.
The aim of this study was to evaluate the efficacy of a treat-and-extend (TAE) regimen using intravitreal injection of aflibercept (IVA) for typical age-related macular degeneration (tAMD).
We retrospectively studied 61 treatment-naïve eyes with tAMD. Best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), number of injections, and complications during 2 years were evaluated.
BCVA significantly improved by on average 0.13 logMAR units, and CMT and CCT significantly decreased after 2 years. The number of injections was on average 13.6. In the second year, eyes with classic choroidal neovascularization (CNV) needed significantly fewer treatments than eyes with occult CNV. Fourteen eyes, which developed subfoveal fibrosis, showed significantly poorer BCVA after 2 years. Subfoveal fibrosis was significantly common in classic CNV.
A TAE regimen using IVA for tAMD might be effective for improving BCVA and exudative changes. The exudation may be suppressed with fewer treatments in classic CNV compared to occult CNV.
本研究旨在评估玻璃体内注射阿柏西普（IVA）的治疗并延长（TAE）方案对典型年龄相关性黄斑变性（tAMD）的疗效。
我们回顾性研究了61只初治的tAMD患眼。评估了2年内的最佳矫正视力（BCVA）、中心黄斑厚度（CMT）、中心脉络膜厚度（CCT）、注射次数及并发症。
2年后，BCVA平均显著提高0.13 logMAR单位，CMT和CCT显著降低。平均注射次数为13.6次。在第二年，典型脉络膜新生血管（CNV）患眼所需治疗次数显著少于隐匿性CNV患眼。14只发生黄斑下纤维化的患眼在2年后BCVA显著较差。黄斑下纤维化在典型CNV中显著常见。
使用IVA的TAE方案治疗tAMD可能对改善BCVA和渗出性改变有效。与隐匿性CNV相比，典型CNV通过较少的治疗次数可能就能抑制渗出。
